Adma Biologics, Inc 8-K, filed Oct 2, 2023
Adma Biologics, Inc. (ADMA)
8-K
2023-10-02
For: 2023-09-28
View Original
Added on
April 04, 2026
About this 8-K
Adma Biologics, Inc filed this 8-K on October 2, 2023, reporting on events of September 28, 2023.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 28, 2023
|
|
|
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (201 ) 478-5552
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
| Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On September 28, 2023, the Board of Directors (the “Board”) of ADMA Biologics, Inc. (the “Company”) appointed Alison C. Finger to serve on the Board as a
Class I director with a term expiring at the Company’s 2026 annual meeting of stockholders.
Ms. Finger served as Chief Commercial Officer at bluebird bio, Inc., a biotechnology company, or bluebird, from August 2015 to January 2021. Prior to
bluebird, Ms. Finger served at Bristol-Myers Squibb Company, a pharmaceutical company, or BMS, in roles with increasing responsibility, including as Vice President, Global Commercialization Virology from July 2004 to June 2007, Managing Director,
Australia & New Zealand from July 2007 to May 2009, VP Global Commercialization, Alzheimer’s/Neuroscience from May 2009 to December 2012 and VP Global Commercialization, Hematology from December 2012 to May 2014. Ms. Finger previously served as a
member of the board of directors of Decibel Therapeutics, a biotechnology company, from December 2021 until the acquisition of Decibel Therapeutics in September 2023 and as a member of the board of directors of VBL Therapeutics, a biotechnology
company from July 2021 to August 2022. Ms. Finger has a B.A. from St. Lawrence University and an M.B.A. from the Fuqua School of Business at Duke University.
There is no arrangement or understanding between Ms. Finger and any other person pursuant to which Ms. Finger was selected to serve as a director of the
Company, nor is Ms. Finger a party to any transactions required to be disclosed under Item 404(a) of Regulation S-K involving the Company. As a non-employee director, Ms. Finger is eligible to participate in the ADMA Biologics, Inc. 2022 Equity
Compensation Plan. For her service on the Board, Ms. Finger will receive compensation in accordance with the Company’s general policies for compensation of non-employee directors, including, without limitation, an initial grant of options to purchase
98,870 shares of the Company’s common stock upon joining the Board.
| Item 9.01 |
Exhibits.
|
(d) Exhibits
|
Exhibit No.
|
Description
|
|
104
|
Cover Page Interactive Data File (embedded with the Inline XBRL document)
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
October 2, 2023
|
ADMA Biologics, Inc.
|
||
|
By:
|
/s/ Brian Lenz
|
||
|
Name:
|
Brian Lenz
|
||
|
Title:
|
Executive Vice President and Chief Financial Officer
|
||
3